Search Weight Loss Topics:




Nov 7

SOTIO Exercises Second Target Option Under Existing Collaboration with NBE-Therapeutics to Develop Next-Generation Antibody-Drug Conjugates – b3c…

BASEL, Switzerland and PRAGUE, Czech Republic , November 07, 2019 / B3C newswire / -- NBE-Therapeutics AG andSOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation antibody-drug conjugate (ADC) under their existing license and collaboration agreement. NBE andSOTIO will collaborate onthediscovery, non-clinical development and manufacturing ofthis second undisclosed target. Thedevelopment will bebased onNBEs proprietary antibody drug conjugate platform, including NBEssite-specific SMAC-technology conjugation anditsnew, highly potent anthracycline toxin platforms. SOTIO will take global responsibility forclinical development, registration andcommercialization oftheADC products.

NBE-Therapeutics new iADC platform creates highly potent and safe immune-stimulatory ADCs with an anthracycline payload, inducing a long-lasting immunological anti-tumor effect. It has shown unprecedented preclinical data in efficacy, as well as safety, in multiple pipeline programs. Its lead program NBE-002 against the ROR1 target has successfully passed the GLP tox study and is in the final stages of CMC. It is expected to begin its first in-human study by mid-2020 for triple negative breast cancer and lung cancer, as well as other cancer indications.

NBE is eligible for the option exercise fee, as well asmilestone payments androyalties based onglobal net product sales. Inaddition, NBE will bereimbursed foritsR&D expenses incurred inconnection withproductdevelopment incollaboration withSOTIO.

Dr. Ulf Grawunder, CEO ofNBE-Therapeutics commented:Weare very enthusiastic that SOTIO has nominated a second ADC program under the existing collaboration agreement between SOTIO and NBE, confirming the high quality of our ADC platform. We have now created a robust and scalable ADC platform that enables us to leverage iADC development in clinical studies for multiple programs. The collaboration with Sotio over the past years has further strengthened our technology and we are very proud to have them on board for a second iADC development program.

Based on the very encouraging data from our first collaboration target with NBE and the SO-N102 program, as well as the data of NBEs proprietary program NBE-002, we have now exercised the second target option in the collaboration, mentions Dr. Radek Spisek, CEO ofSOTIO. NBEs product platform addresses thekey issues oftodays antibody-drug conjugates and hasthepotential toprovide new and superior treatment options forcancer patients.

About NBE-TherapeuticsNBE-Therapeutics is a privately-owned Swiss, Basel-based biotech company, founded in 2012 with the vision of developing next-generation immune-stimulatory antibody drug conjugate (iADC) products. NBE advances its products to clinical proof of concept with the goal of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb Display technology for antibody discovery, its SMAC-Technology for site-specific payload conjugation of toxins to antibodies and a novel highly effective and immune-stimulatory anthracycline-based toxin platform. The company is financially backed by the Boehringer Ingelheim Venture Fund (D), the PPF Group and Novo Holdings (DK) as institutional investors, and by additional Swiss, German and Dutch private investors.

AboutSOTIOSOTIO isaninternational biotechnology company leading theefforts ofPPF Group tobuild adiverse biotechnology portfolio through itsown research & development, collaborations, in-licensing, investments, mergers andacquisitions. Thecompany isdeveloping new medical therapies, focusing onthetreatment ofcancer. Themost advanced project isitsproprietary platform ofactive cellular immunotherapy onthebasis ofdendritic cells. SOTIO isverifying thesafety andefficacy ofitsDCVAC products through multiple Phase ItoPhase IIIclinical trials. One ofitsaffiliates, Cytune Pharma, aFrench biotechnology company focusing ondeveloping novel immunotherapies forthetreatment ofcancer, iscurrently evaluating itsSO-C101 (IL-15-based) lead program inPhase Iclinical trial incollaboration withSOTIO. SOTIO isalso looking topartner withother companies andinstitutions that develop promising oncology therapeutics. SOTIO hasfacilities inEurope, theUnited States, China andRussia andhasall thefunctionalities needed forresearch, clinical development andmarket access in-house.

Contact

NBE Therapeutics AGUlf GrawunderCEO+41 61 633 2230This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords: Humans; Triple Negative Breast Neoplasms; Anthracyclines; Antibodies; Immunoconjugates; Lung Neoplasms; Biotechnology; antibody-drug conjugates

Published by B3C newswire and shared through Newronic

Read the original here:
SOTIO Exercises Second Target Option Under Existing Collaboration with NBE-Therapeutics to Develop Next-Generation Antibody-Drug Conjugates - b3c...

Related Post

Your Full Name
Your Email
Your Phone Number
Select your age (30+ only)
Select Your US State
Program Choice
Confirm over 30 years old Yes
Confirm that you resident in USA Yes
This is a Serious Inquiry Yes
Message:
captcha